Do TZDs Heighten Your Risk of Heart Failure?


By: W. Langbein

Type 2s who take thiazolidinediones (TZDs) such as Avandia and Actos face an increased risk of heart failure, and researchers suggest that physicians should consider alternative therapies.

Researchers studied health insurance claims between 1995 and 2001 for two groups, one with about 5,500 patients who used oral TZDs and another group of 28,100 who did not. Those on TZDs tended to be younger but also more likely to experience coronary artery disease or diabetes complications.

TZD patients experienced an 8.2 percent rate of heart failure compared with 5.3 percent in the control group.

The researchers urge physicians to be alert for symptoms of congestive heart failure, such as shortness of breath, in patients on TZDs and to consider different therapies for patients at risk.

Diabetes Care, November 2003



Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.